Free Trial
→ Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel
NASDAQ:JAZZ

Jazz Pharmaceuticals Q1 2026 Earnings Results & Report

Jazz Pharmaceuticals logo
$244.86 -3.38 (-1.36%)
As of 11:23 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Jazz Pharmaceuticals reported Q1 2026 earnings on March 31, 2026. The company reported EPS of $6.34, while revenue was $1.07 billion.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens

Jazz Pharmaceuticals EPS Results

Actual EPS
$6.34
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Jazz Pharmaceuticals Revenue Results

Actual Revenue
$1.07 billion
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Jazz Pharmaceuticals Q1 2026 Earnings FAQ

Jazz Pharmaceuticals (NASDAQ:JAZZ) reported earnings of $6.34 per share for Q1 2026. The report was announced on Tuesday, March 31, 2026.

Jazz Pharmaceuticals reported revenue of $1.07 billion for Q1 2026.

Jazz Pharmaceuticals Earnings Headlines

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Stock Has Consensus Target Price of $293.45 According to Analysts
November 9 at 2:44 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31187253
Jazz Pharmaceuticals (NASDAQ:JAZZ) Downgraded by Wall Street Zen to "Hold"
November 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31182872
Trump, Schiff and Dalio all point to the same warning sign
In 1929, the Dow fell 89 percent and took 25 years to recover. A 60-year-old who held on wasn't made whole until age 85. Today, the national debt sits at 38.86 trillion dollars, a level the market has never faced before. Economists including Peter Schiff and Ray Dalio point to a classic bubble forming.tc pixel
November 12 at 1:00 AM  |  USA Capital Gold (Ad)
Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says
November 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31179755
Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Gets Price Target Bump from Barclays
November 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31179748
Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price Expected to Rise, Morgan Stanley Analyst Says
November 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31179744
See More Jazz Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Jazz Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Jazz Pharmaceuticals and other key companies, straight to your email.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals (NASDAQ:JAZZ) is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets.

Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.

Jazz expanded its portfolio through acquisitions, including the 2021 acquisition of GW Pharmaceuticals, which added Epidiolex and other cannabinoid-based medicines. Bruce Cozadd, a company co-founder, serves as chairman and chief executive officer.

View Jazz Pharmaceuticals Profile
Earnings Tools